Published: 27 March 2024
Author(s): Santiago Jiménez-Marrero, Miguel Cainzos-Achirica, David Monterde, Emili Vela, Cristina Enjuanes, Sergi Yun, Alberto Garay, Pedro Moliner, Miriam Corbella, Sílvia Jovells-Vaqué, Lídia Alcoberro, Alexandra Pons-Riverola, Raul Ramos-Polo, Herminio Morillas, Joan Antoni Gómez-Hospital, Josep Comin-Colet
Issue: May 2024
Section: Original Article

The inhibition of the renin-angiotensin-aldosterone system (RAAS) is a essential aspect of the medical treatment of several chronic cardiovascular, metabolic, and renal conditions. It plays a vital role in managing chronic heart failure (CHF), particularly CHF with reduced ejection fraction, and also in chronic kidney disease (CKD), diabetes mellitus (DM), ischemic heart disease (IHD), and hypertension (HTN). Extensive evidence from randomized clinical trials supports the benefits of RAAS inhibition (RAASI) in these patient populations, demonstrating improvements in important clinical outcomes, including mortality and hospitalizations.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.